130 related articles for article (PubMed ID: 20363971)
1. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands.
Oberg HH; Ly TT; Ussat S; Meyer T; Kabelitz D; Wesch D
J Immunol; 2010 May; 184(9):4733-40. PubMed ID: 20363971
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
Bocian K; Borysowski J; Wierzbicki P; Wyzgal J; Klosowska D; Bialoszewska A; Paczek L; Górski A; Korczak-Kowalska G
Nephrol Dial Transplant; 2010 Mar; 25(3):710-7. PubMed ID: 19903662
[TBL] [Abstract][Full Text] [Related]
3. TLR2 agonists enhance CD8+Foxp3+ regulatory T cells and suppress Th2 immune responses during allergen immunotherapy.
Tsai YG; Yang KD; Niu DM; Chien JW; Lin CY
J Immunol; 2010 Jun; 184(12):7229-37. PubMed ID: 20483759
[TBL] [Abstract][Full Text] [Related]
4. A dual action of rheumatoid arthritis synovial fibroblast IL-15 expression on the equilibrium between CD4+CD25+ regulatory T cells and CD4+CD25- responder T cells.
Benito-Miguel M; García-Carmona Y; Balsa A; Pérez de Ayala C; Cobo-Ibáñez T; Martín-Mola E; Miranda-Carús ME
J Immunol; 2009 Dec; 183(12):8268-79. PubMed ID: 20007590
[TBL] [Abstract][Full Text] [Related]
5. TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes.
Lindner SC; Köhl U; Maier TJ; Steinhilber D; Sorg BL
J Leukoc Biol; 2009 Aug; 86(2):389-99. PubMed ID: 19401382
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 2 activators modulate oral tolerance in mice.
Tunis MC; Dawod B; Carson KR; Veinotte LL; Marshall JS
Clin Exp Allergy; 2015 Nov; 45(11):1690-702. PubMed ID: 26242919
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
Ahn JS; Krishnadas DK; Agrawal B
Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
[TBL] [Abstract][Full Text] [Related]
8. Regulation of T cell activation by TLR ligands.
Oberg HH; Juricke M; Kabelitz D; Wesch D
Eur J Cell Biol; 2011; 90(6-7):582-92. PubMed ID: 21292344
[TBL] [Abstract][Full Text] [Related]
9. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C.
Wang JP; Zhang Y; Wei X; Li J; Nan XP; Yu HT; Li Y; Wang PZ; Bai XF
APMIS; 2010 Apr; 118(4):261-70. PubMed ID: 20402671
[TBL] [Abstract][Full Text] [Related]
10. CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex.
Nakata T; Yasuda M; Fujita M; Kataoka H; Kiura K; Sano H; Shibata K
Cell Microbiol; 2006 Dec; 8(12):1899-909. PubMed ID: 16848791
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 2 ligands inhibit TH2 responses to mite allergen.
Taylor RC; Richmond P; Upham JW
J Allergy Clin Immunol; 2006 May; 117(5):1148-54. PubMed ID: 16675345
[TBL] [Abstract][Full Text] [Related]
12. Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol.
Mjösberg J; Svensson J; Johansson E; Hellström L; Casas R; Jenmalm MC; Boij R; Matthiesen L; Jönsson JI; Berg G; Ernerudh J
J Immunol; 2009 Jul; 183(1):759-69. PubMed ID: 19535629
[TBL] [Abstract][Full Text] [Related]
13. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses.
Venken K; Thewissen M; Hellings N; Somers V; Hensen K; Rummens JL; Stinissen P
J Immunol Methods; 2007 Apr; 322(1-2):1-11. PubMed ID: 17368474
[TBL] [Abstract][Full Text] [Related]
14. Ethylene-Diamine-Tetra-Acetate (EDTA) mimics the effect of regulatory T cells in suppression assays: a potential pitfall when using AutoMACS-separated cells.
Dige A; Hvas CL; Kelsen J; Deleuran B; Dahlerup JF; Agnholt J
J Immunol Methods; 2010 Feb; 353(1-2):141-4. PubMed ID: 19958773
[TBL] [Abstract][Full Text] [Related]
15. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y
Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841
[TBL] [Abstract][Full Text] [Related]
16. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.
Tsaknaridis L; Spencer L; Culbertson N; Hicks K; LaTocha D; Chou YK; Whitham RH; Bakke A; Jones RE; Offner H; Bourdette DN; Vandenbark AA
J Neurosci Res; 2003 Oct; 74(2):296-308. PubMed ID: 14515359
[TBL] [Abstract][Full Text] [Related]
17. In vivo anti- and pro-tumour activities of the TLR2 ligand FSL-1.
Kiura K; Hasebe A; Saeki A; Segawa T; Okada F; Shamsul HM; Ohtani M; Into T; Inoue N; Wakita M; Shibata K
Immunobiology; 2011 Aug; 216(8):891-900. PubMed ID: 21496943
[TBL] [Abstract][Full Text] [Related]
18. De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid.
Wang J; Huizinga TW; Toes RE
J Immunol; 2009 Sep; 183(6):4119-26. PubMed ID: 19717521
[TBL] [Abstract][Full Text] [Related]
19. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis.
Zhang Y; Wang HB; Chi LJ; Wang WZ
Immunol Lett; 2009 Jan; 122(1):52-7. PubMed ID: 19111574
[TBL] [Abstract][Full Text] [Related]
20. CD4-mediated functional activation of human CD4+CD25+ regulatory T cells.
Becker C; Kubach J; Wijdenes J; Knop J; Jonuleit H
Eur J Immunol; 2007 May; 37(5):1217-23. PubMed ID: 17407195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
